JP7241426B2 - 増殖性障害の治療のための投薬レジメン - Google Patents

増殖性障害の治療のための投薬レジメン Download PDF

Info

Publication number
JP7241426B2
JP7241426B2 JP2020555189A JP2020555189A JP7241426B2 JP 7241426 B2 JP7241426 B2 JP 7241426B2 JP 2020555189 A JP2020555189 A JP 2020555189A JP 2020555189 A JP2020555189 A JP 2020555189A JP 7241426 B2 JP7241426 B2 JP 7241426B2
Authority
JP
Japan
Prior art keywords
curcumin
lysophosphatidylcholine
weeks
hours
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020555189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521130A (ja
Inventor
ピーター ソルディロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signpath Pharma Inc
Original Assignee
Signpath Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signpath Pharma Inc filed Critical Signpath Pharma Inc
Publication of JP2021521130A publication Critical patent/JP2021521130A/ja
Priority to JP2022205330A priority Critical patent/JP2023030106A/ja
Application granted granted Critical
Publication of JP7241426B2 publication Critical patent/JP7241426B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020555189A 2018-04-09 2019-03-28 増殖性障害の治療のための投薬レジメン Active JP7241426B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022205330A JP2023030106A (ja) 2018-04-09 2022-12-22 増殖性障害の治療のための投薬レジメン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862655095P 2018-04-09 2018-04-09
US62/655,095 2018-04-09
PCT/US2019/024495 WO2019199469A1 (en) 2018-04-09 2019-03-28 Dosing regimens for treatment of proliferative disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022205330A Division JP2023030106A (ja) 2018-04-09 2022-12-22 増殖性障害の治療のための投薬レジメン

Publications (2)

Publication Number Publication Date
JP2021521130A JP2021521130A (ja) 2021-08-26
JP7241426B2 true JP7241426B2 (ja) 2023-03-17

Family

ID=68164516

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020555189A Active JP7241426B2 (ja) 2018-04-09 2019-03-28 増殖性障害の治療のための投薬レジメン
JP2022205330A Pending JP2023030106A (ja) 2018-04-09 2022-12-22 増殖性障害の治療のための投薬レジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022205330A Pending JP2023030106A (ja) 2018-04-09 2022-12-22 増殖性障害の治療のための投薬レジメン

Country Status (11)

Country Link
US (2) US11813356B2 (https=)
EP (1) EP3773529B1 (https=)
JP (2) JP7241426B2 (https=)
KR (2) KR20240027843A (https=)
CN (1) CN112272555A (https=)
AU (1) AU2019250832B2 (https=)
CA (1) CA3096591C (https=)
ES (1) ES3061642T3 (https=)
MX (1) MX2020010651A (https=)
TW (1) TWI737974B (https=)
WO (1) WO2019199469A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI737974B (zh) 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案
EP4675742A1 (en) 2023-02-28 2026-01-07 Panasonic Intellectual Property Management Co., Ltd. Non-aqueous electrolyte secondary battery

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060067998A1 (en) 2004-03-05 2006-03-30 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
JP2015522810A (ja) 2012-06-14 2015-08-06 サインパス ファルマ, インク.Signpath Pharma, Inc. リポソームのクルクミン及びその代謝産物であるテトラヒドロクルクミンの薬物動態を測定するための方法及びシステム
JP2016540781A (ja) 2013-12-18 2016-12-28 サインパス ファルマ, インク.Signpath Pharma, Inc. 心筋ｉｋｒチャネルの薬剤誘発性阻害のリポソームによる軽減
US20170079934A1 (en) 2015-09-18 2017-03-23 Signpath Pharma Inc. Treatment for glioblastoma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244448B2 (en) * 2000-06-30 2007-07-17 Tekmira Pharmaceuticals Corporation Liposomal antineoplastic drugs and uses thereof
US8563525B2 (en) * 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
US8784881B2 (en) * 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
CN1973834A (zh) * 2006-12-15 2007-06-06 中国科学院长春应用化学研究所 姜黄素用于制备治疗恶性肿瘤耐药的逆转药物的应用
PT2146721E (pt) 2007-05-15 2013-07-18 Otsuka Pharma Co Ltd Métodos de utilização de antagonistas da vasopressina com agentes quimioterapeuticos de antraciclina para reduzir a cardiotoxicidade e/ou melhorar a sobrevivência
CN101766619B (zh) * 2008-12-30 2011-08-24 武汉大学 一种治疗恶性肿瘤的药物组合物及应用
EP2501372A4 (en) * 2009-11-19 2013-04-10 Signpath Pharma Inc INTRAVENOUS INFUSION OF CURCUMIN AND CALCIUM CHANNEL BLOCKER
DE112013004278T5 (de) * 2012-08-31 2015-05-21 Signpath Pharma Inc. Curcumin-Er, ein liposomales PLGA-Nanocurcumin mit verlängerter oder verzögerter Freisetzung zur Minimierung der QT-Verlängerung für eine Krebstherapie
US20150147385A1 (en) * 2013-11-22 2015-05-28 Signpath Pharma, Inc. Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders
KR101755245B1 (ko) 2015-08-12 2017-07-07 연세대학교 원주산학협력단 단량체 염을 이용한 폴리이미드 복합체 제조방법
TWI737974B (zh) 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060067998A1 (en) 2004-03-05 2006-03-30 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
JP2015522810A (ja) 2012-06-14 2015-08-06 サインパス ファルマ, インク.Signpath Pharma, Inc. リポソームのクルクミン及びその代謝産物であるテトラヒドロクルクミンの薬物動態を測定するための方法及びシステム
JP2016540781A (ja) 2013-12-18 2016-12-28 サインパス ファルマ, インク.Signpath Pharma, Inc. 心筋ｉｋｒチャネルの薬剤誘発性阻害のリポソームによる軽減
US20170079934A1 (en) 2015-09-18 2017-03-23 Signpath Pharma Inc. Treatment for glioblastoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
International Journal of Clinical Pharmacology and Therapeutics，2015年，Vol.53, No.1，pp.54-65

Also Published As

Publication number Publication date
ES3061642T3 (en) 2026-04-06
CA3096591C (en) 2023-06-27
US20240050372A1 (en) 2024-02-15
AU2019250832B2 (en) 2022-10-27
CN112272555A (zh) 2021-01-26
US11813356B2 (en) 2023-11-14
EP3773529C0 (en) 2025-12-24
EP3773529A1 (en) 2021-02-17
EP3773529B1 (en) 2025-12-24
TWI737974B (zh) 2021-09-01
JP2023030106A (ja) 2023-03-07
KR102637598B1 (ko) 2024-02-16
AU2019250832A1 (en) 2020-10-29
JP2021521130A (ja) 2021-08-26
WO2019199469A1 (en) 2019-10-17
TW201946613A (zh) 2019-12-16
KR20240027843A (ko) 2024-03-04
US12551436B2 (en) 2026-02-17
KR20200141062A (ko) 2020-12-17
US20210161815A1 (en) 2021-06-03
EP3773529A4 (en) 2021-12-22
MX2020010651A (es) 2021-01-15
CA3096591A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
Greil et al. A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer
Dong et al. Comparative study of mucoadhesive and mucus-penetrative nanoparticles based on phospholipid complex to overcome the mucus barrier for inhaled delivery of baicalein
JP6861682B2 (ja) コエンザイムＱ１０（ＣｏＱ１０）の静脈内投与用製剤およびその使用方法
JP5645954B2 (ja) イリノテカン又はその塩酸塩のリポソーム及びその製造方法
DK2879502T3 (en) COCHLEATES PREPARED WITH SOYAPHOSPHATIDYLSERINE
US12551436B2 (en) Dosing regimens for treatment of proliferative disorders
CN105338973A (zh) 使用辅酶q10联合疗法治疗癌症
EA032345B1 (ru) Способ лечения рака с использованием кофермента q10
EP3861987A1 (en) Combination medicine comprising drug-encapsulating liposome composition and platinum preparation
CN115364218A (zh) 一种特定药脂比的药物组合物在抗肿瘤中的应用
US20150147385A1 (en) Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders
HK40044373A (en) Dosing regimens for treatment of proliferative disorders
TWI607766B (zh) 核酸、醫用奈米粒子組以及醫藥組合物
WO2015148985A1 (en) Liposomal drug encapsulation
Ganji et al. Formulation, excipient properties and pharmacological activities of catechin liposomes
WO2020023436A1 (en) Cell membrane lipid-extracted nanoparticles (clens) for selective targeting, image analysis and cancer therapy
WO2013097266A1 (zh) 一种包裹ly294002的药物制剂
HK1259723A1 (en) Echinomycin formulation, method of making and method of use thereof
HK1211181B (en) Cochleates made with soy phosphatidylserine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221222

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221222

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230105

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230228

R150 Certificate of patent or registration of utility model

Ref document number: 7241426

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250